###### Key questions

What is already known about this topic?
=======================================

-   With advancements in HIV treatment and care, morbidity and mortality associated with HIV have decreased in many limited resource settings.

-   Since people are living longer lives and experiencing less complications as a result of HIV, patients are now presenting to primary care providers with non-communicable diseases, including hypertension.

-   At the population level, there is mixed evidence from low and middle income countries on the prevalence of hypertension among HIV-positive patients and its correlates.

What are the new findings?
==========================

-   We retrospectively performed a chart review on 1996 patients from 2009 to 2013 to identify hypertension and correlates among patients attending an ambulatory HIV clinic in Kampala, Uganda.

-   The overall prevalence of hypertension was 418/1996 (20.9%). This rose from 16.9% in 2009 to 32.3% in 2013.

Recommendations for policy
==========================

-   There is a need to better integrate NCD care within the HIV clinical settings.

Introduction {#s1}
============

There has been a substantial reduction in HIV-associated morbidity and mortality as a result of the global scale-up of antiretroviral therapy (ART). This is particularly true in low and middle income countries, such as those in the sub-Saharan African region, which bear the largest burden of HIV.[@R1] This reduction in mortality has substantially increased life expectancy, with estimates now approaching that of the general population.[@R5] Now that HIV-positive individuals are living longer lives, there has been increased attention towards the emerging dual burden of HIV and non-communicable diseases (NCDs), such as hypertension.

Hypertension in HIV-positive patients has been reported to be as low as 8.7% and as high as 45.9% in low and middle income countries.[@R9] [@R10] Compared with the general population, some studies have suggested that hypertension is more prevalent among HIV-positive patients,[@R9] [@R11] whereas other studies have reported that patients with HIV have lower levels of hypertension, compared with the general population.[@R12] [@R13] Although there has been a comparable response to therapy for patients with hypertension with or without HIV infection,[@R9] the dual burden of NCDs and HIV provides a challenge to weak healthcare systems in low and middle income countries.[@R14] Establishing the magnitude of hypertension among HIV-positive patients and documenting the quality of care for these conditions within the HIV care setting provides an opportunity for improved care. The aim of this study was to determine the prevalence of hypertension, trends and associated factors among adults attending an ambulatory HIV clinic from 2009 to 2013 in Kampala, Uganda.

Methods {#s2}
=======

Study design and population {#s2a}
---------------------------

This was a retrospective study conducted at the Mulago AIDS Clinic, an outpatient clinic of Makerere University Joint AIDS Programme (MJAP), located in Kampala, Uganda. This clinic, supported by the President\'s Emergency Plan for AIDS Relief (PEPFAR), provides comprehensive HIV services to over 14 000 HIV-positive individuals, with the majority over the age of 18 years. Most of the patients live within a 20 km radius of the clinic. The HIV treatment guidelines (2014) at the clinic at the time of the study included eligibility for all patients with a CD4+ T-cell count of ≤500 cells/mm^3^, or the presence of WHO clinical disease stage 3 or 4, pregnancy, hepatitis B co-infection, HIV-associated nephropathy, or patients under 15 years of age. The clinic follows the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7) clinical guidelines for the detection and management of hypertension.

Patients were eligible for inclusion if they were at least 18 years of age and visited the clinic between 2009 and 2014. Patients were randomly selected based on their year of intake into the HIV clinic and each patient was given a unique identifier at enrolment, so that patients do not appear on more than one sampling frame for each year. From this sampling frame, 400 patient charts from each year were randomly selected using a random number generator. For each of the 400 patient files selected, study variables were extracted.

Study variables {#s2b}
---------------

The primary outcome variable was prevalence of hypertension. In each year, patients were considered as hypertensive if their systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg at three consecutive measurements separated by at least 2 weeks and taken after 5--10 min of rest in a sitting position or if they were known to be hypertensive and on treatment.[@R15] Adequate control for hypertension was defined as systolic blood pressure \<140 mm Hg and diastolic blood pressure \<90 mm Hg at the second and successive visits.[@R15]

Additionally, we extracted data on demographic, clinical and biological characteristics including: WHO HIV disease stage, whether the patient was on ART, body mass index (BMI) and Karnofsky score that measures the degree of patient\'s functional impairment on a scale of 0--100.

Statistical analysis {#s2c}
--------------------

Descriptive statistics were used to characterise the data. Prevalence of hypertension was calculated as the proportion of the study sample with a positive diagnosis, overall, and in each study year. Bivariable logistic regression was used to estimate the strength of the association between each study variable and the primary outcome, hypertension. A multivariable logistic model, adjusted for age and sex, was also constructed. Results are presented as ORs and adjusted ORs along with associated 95% CIs. All statistical tests were two-sided with α set at 0.05. Analyses were performed using STATA V.12 (StataCorp, College Station, Texas, USA).

Results {#s3}
=======

In total, 2000 (400 per year from 2009 to 2013) patients were randomly selected from a sampling frame of 13 550. In 2009, four patients did not have any information on the outcome, so the final analytic sample consisted of 1996 patients. Of these, 418 were considered hypertensive, an overall study prevalence of 20.9%. [Table 1](#BMJGH2016000055TB1){ref-type="table"} displays patient demographic and clinical factors stratified by the presence of hypertension, while [table 2](#BMJGH2016000055TB2){ref-type="table"} displays the characteristics of the sample by each year sampled.

###### 

Demographic and clinical factors stratified by hypertension

                          No hypertension   Hypertension   
  ----------------------- ----------------- -------------- ---------
  Age, years                                               
   \<20                   41 (2.7)          5 (1.0)        \<0.001
   20--29                 578 (38.2)        144 (29.9)     
   30--39                 629 (41.5)        191 (39.7)     
   40--49                 213 (14.1)        99 (20.6)      
   \>50                   54 (3.6)          42 (8.7)       
  Sex                                                      
   Female                 1036 (68.3)       273 (56.6)     \<0.001
   Male                   481 (31.7)        209 (43.4)     
  BMI, kg/m^2^                                             
   18--24                 1184 (78.8)       329 (68.4)     \<0.001
   25--29                 222 (14.8)        97 (20.2)      
   30+                    74 (4.9)          37 (7.7)       
  On ART                                                   
   No                     281 (18.5)        78 (16.2)      \<0.001
   Yes                    1236 (81.5)       404 (83.8)     
  WHO HIV disease stage                                    
   Stage 1 and 2          1066 (70.3)       385 (79.9)     \<0.001
   Stage 3 and 4          451 (29.7)        97 (20.1)      
  Karnofsky score                                          
   0--80                  122 (9.6)         14 (3.6)       \<0.001
   81--100                1146 (90.4)       371 (96.4)     

ART, antiretroviral therapy; BMI, body mass index.

###### 

Sample characteristics by year, 2009--2013

                          n            p Value                                             
  ----------------------- ------------ ------------ ------------ ------------ ------------ ---------
  Mean age (SE)           33.7 (0.5)   34.1 (0.4)   33.5 (0.4)   32.4 (0.5)   31.7 (0.5)   ---
  Age, years                                                                               
   \<20                   8            3            4            6            25           \<0.001
   20--29                 139          124          135          176          148          
   30--39                 164          182          173          144          157          
   40--49                 62           71           65           53           61           
   \>50                   25           20           21           20           10           
  Sex                                                                                      
   Female                 250          246          269          271          273          0.154
   Male                   148          154          129          128          131          
  BMI, kg/m^2^                                                                             
   18--24                 332          324          291          286          280          \<0.001
   25--29                 45           52           77           80           65           
   30+                    20           22           24           31           55           
  WHO HIV disease stage                                                                    
   Stage 1 and 2          258          264          279          316          334          \<0.001
   Stage 3 and 4          140          136          119          83           70           
  Karnofsky score                                                                          
   0--80                  32           68           9            9            18           \<0.001
   81--100                365          331          64           389          368          

BMI, body mass index.

[Figure 1](#BMJGH2016000055F1){ref-type="fig"} shows the prevalence of hypertension by study year. Each year, the prevalence of hypertension increased. The prevalence in 2009 was 67/396 (16.9%), in 2010 was 76/400 (19.0%), in 2011 was 96/400 (24.0%), in 2012 was 114/400 (28.5%), and in 2013 was 129/400 (32.3%). Of the patients with hypertension, 96/418 (23.0%) were receiving adequate treatment. The proportion of adequately treated patients rose from 14/53 (26.4%) in 2009 to 37/105 (35.2%) in 2013. Men had a higher prevalence of hypertension each year compared with women.

![Overall prevalence of hypertension by year of chart review. Note: Table indicates number of patients each year with each systolic blood pressure (SBP) ≥140 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg, as well as SBP≥140 mm Hg and DBP≥90 mm Hg.](bmjgh2016000055f01){#BMJGH2016000055F1}

[Table 3](#BMJGH2016000055TB3){ref-type="table"} displays the results of bivariable and multivariable logistic regression to estimate the strength of the association between each demographic and clinical factor and the presence of hypertension. Patients \>50 years of age had 3.12 times the odds of hypertension compared with patients aged 20--29 years (95% CI 2.00 to 4.85). Men had 1.65 times the odds of hypertension compared with women (95% CI 1.34 to 2.03) and patients with a BMI of 35--39 kg/m^2^ had 3.93 times the odds of hypertension compared with patients with a BMI \<25 kg/m^2^. Patients with a WHO disease staging of 3 or 4 had 0.60 times the odds of hypertension compared with patients with stage 1 or 2 (95% CI 0.46 to 0.76) and patients with a Karnofsky score of 81--100 had 2.82 times the odds of hypertension compared with patients with a score of 0--80 (95% CI 1.66 to 5.19). After adjusting for age and sex, the adjusted ORs changed minimally, indicating that confounding had a minimal influence on the model.

###### 

Bivariable and multivariable logistic regression identifying the strength of the association between demographic and clinical factors and presence of hypertension

                          Unadjusted            Adjusted
  ----------------------- --------------------- ---------------------
  Age, years                                    
   \<20                   0.49 (0.17 to 1.15)   0.43 (0.13 to 1.09)
   20--29                 Ref (---)             ---
   30--39                 1.22 (0.96 to 1.56)   1.31 (1.00 to 1.73)
   40--49                 1.86 (1.38 to 2.52)   2.06 (1.45 to 2.91)
   \>50                   3.12 (2.00 to 4.85)   4.05 (2.40 to 6.83)
  Sex                                           
   Female                 Ref (---)             ---
   Male                   1.65 (1.34 to 2.03)   2.02 (1.55 to 2.63)
  BMI, kg/m^2^                                  
   18--24                 Ref (---)             ---
   25--29                 1.57 (1.20 to 2.05)   \<0.01
   30+                    2.04 (1.43 to 2.89)   \<0.01
  On ART                                        
   No                     Ref (---)             ---
   Yes                    1.18 (0.90 to 1.56)   0.24
  WHO HIV disease stage                         
   Stage 1 and 2          Ref (---)             ---
   Stage 3 and 4          0.60 (0.46 to 0.76)   \<0.01
  Karnofsky score                               
   0--80                  Ref (---)             ---
   81--100                2.82 (1.66 to 5.19)   \<0.01

AOR, adjusted OR; ART, antiretroviral therapy; BMI, body mass index.

Discussion {#s4}
==========

This study sought to determine the prevalence, trend and correlates of hypertension among adults attending an ambulatory HIV clinic in Kampala, Uganda. We found a rise in the prevalence of hypertension from 2009 to 2013, from 16.9% to 32.2%. Similarly, HIV prevalence rose from 6.4% in 2005 to 7.3% in 2014 (The Joint United Nations Programme on HIV/AIDS (UNAIDS), Gap Report). This demonstrates a rising double burden of HIV and hypertension, consistent with reports that as the proportion of HIV-positive patients achieving viral suppression on combination ART grows larger and these patients age, they are experiencing a widening spectrum of non-AIDS-related diseases.[@R1]

Our study found an overall prevalence of 24.1% and a rising prevalence by year from 16.9% in 2009 to 32.3% in 2013. This is most likely due to the rising age of the patients accessing HIV care as well as the number of patients being put on antiretroviral therapy (ART). There might also be other factors which may not have been uncovered by the current study due to its retrospective nature. Compared with the general population in Uganda, the prevalence of hypertension in HIV-positive adults is within a similar range (21.2% vs 27.2%).[@R16] Mateen *et al*[@R10] in Uganda similarly reported a 28% prevalence of hypertension and 49% in those above 50 years with similar risk factors. In another Ugandan study, Sander *et al*[@R9] reported a lower prevalence of hypertension 8.0%, although when they considered only one elevated blood pressure reading, the prevalence rose to 26.3%. In contrast to Sander *et al*,[@R9] where 83% of participants diagnosed with hypertension were on antihypertensive medications, in our study only 20.9% were on recommended treatment for hypertension. In both studies, the most commonly used drugs were β-blockers and calcium channel blockers.[@R9]

Our results provide evidence that hypertension has become an important NCD in the HIV-positive population with prevalence rates similar to that of the general population. In addition, our study shows that management of HIV-positive patients with hypertension is still inadequate. This is partly explained by the current HIV care guidelines in Uganda, which do not routinely include an NCD programme for HIV-positive patients attending the ambulatory clinics. Furthermore, most of the effort from the government and international agencies is currently focusing on HIV, tuberculosis and malaria, with less attention to the rising burden of hypertension in the HIV ageing population. Justice[@R1] recommends that focus must shift from a narrow interest in CD4 counts, HIV RNA and AIDS defining illnesses to determining the optimal management of HIV infection as a complex chronic disease in which the causes of morbidity and mortality are multiple and overlapping. We need a new paradigm of care with which to maximise functional status, minimise frailty and prolong life expectancy.[@R1] The authors propose a composite index that summarises a patient's risk of morbidity and mortality.

In this era of an ageing sub-Saharan African population on ART, we expect more patients to present with hypertension and other chronic conditions. This has become a substantial burden on resource-limited countries to manage a dual epidemic of infectious and chronic diseases. Few NCD programmes have been incorporated into HIV care and this highlights the importance of implementing screening, early diagnosis, and prevention measures for hypertension and other chronic diseases.

Our study has several strengths. The study was conducted in an ambulatory clinic, which serves a large proportion of the patients with HIV in urban Uganda. However, MJAP, being a centre of excellence in HIV, may not truly reflect what is happening elsewhere in the country where the access to expert service care may be more limited. Although we cannot use these data from a specialised urban HIV clinic to generalise hypertension care in Uganda, the findings demonstrate a missed opportunity for comprehensive care even among patients who frequently interface with healthcare providers. The findings therefore highlight a need for healthcare providers to develop indicators which can be used to monitor for improved care beyond HIV, in HIV-infected individuals with comorbidity. Additionally, the interpretation of our results must take into account some limitations. Most importantly, this was a chart review study and no patients were contacted; therefore, there were only a limited number of variables to extract and consider in the analysis. In particular, data on lifestyle factors important to hypertension, such as smoking status and alcohol intake, were sparse and not usable. Therefore, only a limited number of variables were available to construct a bivariable and multivariable model.

In conclusion, our study corroborates other studies that suggest an increasing prevalence of hypertension among HIV-positive patients in Uganda. Identifying risk factors will be important for clinicians to adequately manage a growing dual epidemic of infectious and chronic diseases in sub-Saharan Africa.
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